APLM_OUT_1 [2025-03-20 13:17:05 -0400] 2170 Bytes | 609 tokens | Cum: 609 tkns (7.61% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 01:17:03 PM on Thursday March 20, 2025 ET (UTC-0400), and I'm firing up the spotlight on Apollomics (APLM), moving from 7.96 to 9.5. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Apollomics:

C1 - Dec-20-24 08:00AM - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
C2 - Dec-10-24 04:05PM - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
C3 - Nov-21-24 08:00AM - Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
C4 - Sep-16-24 08:00AM - Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
C5 - Sep-04-24 04:05PM - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
C6 - Aug-14-24 06:00AM - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
C7 - Aug-13-24 08:00AM - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
C8 - Aug-08-24 04:05PM - Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Apollomics (APLM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

APLM_OUT_3 [2025-03-20 13:17:10 -0400] 1047 Bytes | 311 tokens | Cum: 922 tkns (11.53% of 8k)
==========================================================================

Showing C7 (chunk 1 of 10): C7:
**Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial**
Date: Aug-13-24 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2024/08/13/2929124/0/en/Apollomics-Announces-Positive-Preliminary-Data-of-Vebreltinib-in-Patients-with-Non-CNS-MET-Fusion-Solid-Tumors-from-its-Phase-2-SPARTA-Trial.html

August 13, 2024 08:00 ET| Source:Apollomics Inc.Apollomics Inc.

FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) --Apollomics Inc.(Nasdaq:APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today positive preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

APLM_OUT_5 [2025-03-20 13:17:11 -0400] 1045 Bytes | 244 tokens | Cum: 1168 tkns (14.60% of 8k)
==========================================================================

Showing C7 (chunk 2 of 10): of vebreltinib.

“We are very pleased with the preliminary data showing 43% objective response rate in patients with non-CNS MET fusion solid tumors. The results in this specific cohort of patients adds to the accumulating evidence supporting the potential of vebreltinib as a highly selective and efficacious treatment against multiple tumor types harboring MET alterations. Alongside the Avistone data for vebreltinib in the treatment of gliblastoma with PTPRZ1 MET fusions, the clinical evidence for the efficacy of vebreltinib in MET fusions is very encouraging,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “Based on the overall occurrence of these fusions in 0.1-0.3% of solid tumors, we believe the incidence is several thousand per year in the United States. Given the increasing patient access to next-generation sequencing, we expect it will become increas

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

APLM_OUT_7 [2025-03-20 13:17:13 -0400] 1041 Bytes | 250 tokens | Cum: 1420 tkns (17.75% of 8k)
==========================================================================

Showing C7 (chunk 3 of 10): ingly practical to identify and treat these patients with a targeted therapy such as vebreltinb. We look forward to providing additional clinical updates from the SPARTA Phase 2 trial as they become available.”

The pivotal SPARTA trial is a global, multi-cohort, single-arm, open label Phase 2 Study evaluating the efficacy and safety of vebreltinib in a range of MET-altered tumors. As of data analysis cutoff date of July 31, 2024, 14 patients with non-CNS MET fusion solid tumors were included in the study: six with non-small cell lung cancer (NSCLC), one with lung sarcomatoid carcinoma, two with intrahepatic bile duct cancer, one with colon cancer, one with pancreatic cancer, one with breast cancer, one with head and neck cancer, and one with esophageal cancer. Two of the 14 were front-line patients without prior systemic therapy, and twelve were second-line or greater. The preliminary c

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

APLM_OUT_9 [2025-03-20 13:17:14 -0400] 1039 Bytes | 239 tokens | Cum: 1661 tkns (20.76% of 8k)
==========================================================================

Showing C7 (chunk 4 of 10): linical efficacy results are based on independent central radiology review using RECIST v1.1 criteria.

Key preliminary clinical data highlights from 14 patients by RECIST v1.1

Based on these new data, Apollomics is evaluating opportunities for further development of vebreltinib in patients with MET fusions. Patients currently enrolled in the SPARTA MET fusion cohort will continue with treatment and study follow-up.

Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting c-MET dysregulation, vebreltinib has demonstrated strong tumor inhibitory effect in a variety of preclinical c-MET dysregulated human gastric, hepatic, panc

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

APLM_OUT_11 [2025-03-20 13:17:16 -0400] 647 Bytes | 200 tokens | Cum: 1863 tkns (23.29% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-16T21:26:19Z - $APLM | Learn to Evaluate ($APLM) using the Charts (APLM)...
A2 - 2025-03-06T06:33:01Z - $APLM | ($APLM) Trading Advice (APLM)...
A3 - 2025-02-28T20:24:25Z - APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

APLM_OUT_13 [2025-03-20 13:17:17 -0400] 1038 Bytes | 289 tokens | Cum: 2154 tkns (26.92% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**$APLM | Learn to Evaluate ($APLM) using the Charts (APLM)**Date: 2025-03-16Source: {'uri': 'news.stocktradersdaily.com', 'dataType': 'news', 'title': 'Stock Traders Daily'}URL: https://news.stocktradersdaily.com/news_release/24/Learn+to+Evaluate+(APLM)+using+the+Charts_031625045601.htmlOur Signals help define rules-based Trading Plans predicated on the Basic Rules of Tehnical Analysis. Take a trial, review our Index ETF Signals, macro, more...

March 16, 2025, 16:56 pm ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. (Follow on LinkedIn)

When #institutionalinvestors make decisions to buy and sell #stocks they normally want to keep it quiet. However, if we pay close attention we can see what is going on, and make good decisions.. The Apollomics Inc. (NASDAQ: APLM) report below can help you understand how to do this. The trading plans for APLM, are updated in real time for s

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

APLM_OUT_15 [2025-03-20 13:17:19 -0400] 1084 Bytes | 331 tokens | Cum: 2487 tkns (31.09% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-20T13:00:00Z - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
B2 - 2024-08-14T10:00:00Z - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
B3 - 2024-03-04T12:00:00Z - Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
B4 - 2024-01-19T21:15:00Z - Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
B5 - 2024-01-17T21:30:00Z - Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
B6 - 2024-01-03T12:00:00Z - Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APLM_OUT_17 [2025-03-20 13:17:24 -0400] 729 Bytes | 199 tokens | Cum: 2688 tkns (33.60% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/14/2929875/0/en/Apollomics-Reports-First-Half-2024-Financial-Results-and-Highlights-Vebreltinib-Clinical-Progress.htmlApollomics reported progress in its vebreltinib program, including new data in non-CNS MET fusion tumors and NSCLC with MET amplification. The company also announced the closure of its uproleselan program due to negative Phase 3 results from its licensor, GlycoMimetics.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

APLM_OUT_19 [2025-03-20 13:17:25 -0400] 267 Bytes | 68 tokens | Cum: 2841 tkns (35.51% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

APLM_OUT_21 [2025-03-20 13:17:38 -0400] 3323 Bytes | 830 tokens | Cum: 3674 tkns (45.92% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+
| Volume: 33,707 | SMA50: 16.21% | Market Cap: 10.48M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+
| Avg Volume: 15.42K | SMA200: -27.63% | Shs Outstand: 10.84M | Short Float: 0.81% | Employees: - | EPS Surprise: - |
+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+
| Rel Volume: 3.89 | Perf Week: 18.75% | Shs Float: 0.76M | Short Ratio: 0.40 | Debt/Eq: 0.23 | P/E: - |
+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+
| RSI (14): 68.35 | Perf Month: 31.03% | Inst Own: 1.16% | Short Interest: 0.01M | Sales Y/Y TTM: - | Earnings: - |
+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+
| ATR (14): 0.80 | Perf Quarter: 15.43% | Insider Own: 31.31% | Beta: 0.80 | ROE: -149.31% | |
+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+
| SMA20: 30.88% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -262.49% | |
+--------------------+----------------------+----------------------+------------------------+----------------------+-------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

[Company Financial Summary]
[Company Details]
Name: Apollomics Inc. Class A Ordinary Shares
Market Cap: 8777213.4
Shares Outstanding: 1102665
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.087
Average Volume: 5550.0
30-Day High: 9.087
30-Day Low: 6.2
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

Now we've reached the end of the analysis.
You are now requested to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

APLM_OUT_23 [2025-03-20 13:17:40 -0400] 561 Bytes | 131 tokens | Cum: 4056 tkns (50.70% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

APLM_IN_25 [2025-03-20 13:17:40 -0400] 126 Bytes | 29 tokens | Cum: 4092 tkns (51.15% of 8k)
==========================================================================

====================================
[2025-03-20 10:17:40] # Analysis Completed
Elapsed Time: 37.87 seconds